{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:06:04Z","timestamp":1790899564358,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Niemann-Pick disease type C (NP-C) is a rare neurovisceral lysosomal lipid storage disease characterized by progressive neurodegeneration and premature death. While miglustat can stabilize neurological manifestations in later onset forms of NP-C, its efficacy in the early-infantile neurological form has not been demonstrated. In this observational retrospective study, we compared long-term neurodevelopmental outcome and survival between an untreated and a treated group of early infantile NP-C patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data available on all NP-C patients with early infantile neurological onset diagnosed in France between 1990 and 2013 were compiled. Patients with incomplete data or who had died from a systemic perinatal, rapidly fatal form were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten patients were included in the treated group (year of birth: 2006\u20132012), and 16 patients in the untreated group [born 1987\u20132005 (n\u2009=\u200915), 2012 (n\u2009=\u20091)]. The median age at neurological onset was 9\u00a0months (5\u201318) in the treated group, and 12\u00a0months (3\u201318) in the untreated group (p\u2009=\u20090.22). Miglustat therapy was started at a median age of 24.5\u00a0months (9\u201329) and median duration was 30\u00a0months (11\u201356). Gastrointestinal adverse events were reported in 7\/10 patients on miglustat. All patients developed loss of psychomotor acquisitions or additional neurological symptoms despite miglustat therapy. The ages of developmental milestones and neurological involvement did not significantly differ between the two groups. Four patients in the untreated group were lost to follow up. The 22 remaining patients had died by the end of the study and no patient survived beyond the age of 7.4\u00a0years. The median survival age was 4.42\u00a0years in the untreated group and 5.56\u00a0years in the treated group; the Kaplan\u2013Meier survival curves were not significantly different (log-rank test: p\u2009=\u20090.11).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02804-4","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:02:01Z","timestamp":1689926521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: a national French retrospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"C\u00e9cile","family":"Freihuber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahia","family":"Dahmani-Rabehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Brou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Cances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Chabrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Eyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Labarthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Levade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T.","family":"Vanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-4521","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"H\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2804_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-5-16","volume":"51","author":"MT Vanier","year":"2010","unstructured":"Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;51:16.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ymgme.2012.03.012","volume":"1063","author":"MC Patterson","year":"2012","unstructured":"Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012;1063:330\u201344.","journal-title":"Mol Genet Metab"},{"key":"2804_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","volume":"131","author":"T Geberhiwot","year":"2018","unstructured":"Geberhiwot T, Moro A, Dardis A, Ramaswami U, Sirrs S, Pineda Marfa M, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;131:50.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10545-014-9794-4","volume":"381","author":"MT Vanier","year":"2015","unstructured":"Vanier MT. Complex lipid trafficking in Niemann-Pick disease type C. J Inherit Metab Dis. 2015;381:187\u201399.","journal-title":"J Inherit Metab Dis"},{"issue":"75\u201382","key":"2804_CR5","volume":"254","author":"A Gardin","year":"2023","unstructured":"Gardin A, Mussini C, Heron B, Schiff M, Brassier A, Dobbelaere D, et al. A retrospective multicentric study of 34 patients with Niemann-Pick type C disease and early liver involvement in France. J Pediatr. 2023;254(75\u201382): e4.","journal-title":"J Pediatr"},{"key":"2804_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ymgme.2009.06.009","volume":"983","author":"JE Wraith","year":"2009","unstructured":"Wraith JE, Guffon N, Rohrbach M, Hwu WL, Korenke GC, Bembi B, et al. Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. Mol Genet Metab. 2009;983:250\u20134.","journal-title":"Mol Genet Metab"},{"key":"2804_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-8-12","volume":"8","author":"MC Patterson","year":"2013","unstructured":"Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, Drevon H, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis. 2013;8:12.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12883-015-0511-1","volume":"151","author":"J Imrie","year":"2015","unstructured":"Imrie J, Heptinstall L, Knight S, Strong K. Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database. BMC Neurol. 2015;151:257.","journal-title":"BMC Neurol"},{"key":"2804_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13023-022-02200-4","volume":"171","author":"SC Bolton","year":"2022","unstructured":"Bolton SC, Soran V, Marfa MP, Imrie J, Gissen P, Jahnova H, et al. Clinical disease characteristics of patients with Niemann-Pick disease type C: findings from the International Niemann-Pick Disease Registry (INPDR). Orphanet J Rare Dis. 2022;171:51.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1172-7-36","volume":"7","author":"B H\u00e9ron","year":"2012","unstructured":"H\u00e9ron B, Valayannopoulos V, Baruteau J, Chabrol B, Ogier H, Latour P, et al. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. Orphanet J Rare Dis. 2012;7:36.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-018-0844-0","volume":"131","author":"M Pineda","year":"2018","unstructured":"Pineda M, Walterfang M, Patterson MC. Miglustat in Niemann-Pick disease type C patients: a review. Orphanet J Rare Dis. 2018;131:140.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135889","volume":"108","author":"AR Marques","year":"2015","unstructured":"Marques AR, Aten J, Ottenhoff R, van Roomen CP, Herrera Moro D, Claessen N, et al. Reducing GBA2 activity ameliorates neuropathology in Niemann-Pick type C mice. PLoS ONE. 2015;108: e0135889.","journal-title":"PLoS ONE"},{"key":"2804_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","volume":"69","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;69:765\u201372.","journal-title":"Lancet Neurol"},{"key":"2804_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","volume":"994","author":"JE Wraith","year":"2010","unstructured":"Wraith JE, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010;994:351\u20137.","journal-title":"Mol Genet Metab"},{"key":"2804_CR15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/0883073809344222","volume":"253","author":"MC Patterson","year":"2010","unstructured":"Patterson MC, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol. 2010;253:300\u20135.","journal-title":"J Child Neurol"},{"key":"2804_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ymgme.2009.07.003","volume":"983","author":"M Pineda","year":"2009","unstructured":"Pineda M, Wraith JE, Mengel E, Sedel F, Hwu WL, Rohrbach M, et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab. 2009;983:243\u20139.","journal-title":"Mol Genet Metab"},{"key":"2804_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ymgme.2009.11.007","volume":"994","author":"M Pineda","year":"2010","unstructured":"Pineda M, Perez-Poyato MS, O\u2019Callaghan M, Vilaseca MA, Pocovi M, Domingo R, et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol Genet Metab. 2010;994:358\u201366.","journal-title":"Mol Genet Metab"},{"key":"2804_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-015-0284-z","volume":"101","author":"MC Patterson","year":"2015","unstructured":"Patterson MC, Mengel E, Vanier MT, Schwierin B, Muller A, Cornelisse P, et al. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study. Orphanet J Rare Dis. 2015;101:65.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13023-020-01363-2","volume":"151","author":"MC Patterson","year":"2020","unstructured":"Patterson MC, Mengel E, Vanier MT, Moneuse P, Rosenberg D, Pineda M. Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry. Orphanet J Rare Dis. 2020;151:104.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/0925-4439(91)90069-L","volume":"10964","author":"MT Vanier","year":"1991","unstructured":"Vanier MT, Rodriguez-Lafrasse C, Rousson R, Gazzah N, Juge MC, Pentchev PG, et al. Type C Niemann-Pick disease: spectrum of phenotypic variation in disruption of intracellular LDL-derived cholesterol processing. Biochim Biophys Acta. 1991;10964:328\u201337.","journal-title":"Biochim Biophys Acta"},{"key":"2804_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/bs.mcb.2014.10.028","volume":"126","author":"MT Vanier","year":"2015","unstructured":"Vanier MT, Latour P. Laboratory diagnosis of Niemann-Pick disease type C: the filipin staining test. Methods Cell Biol. 2015;126:357\u201375.","journal-title":"Methods Cell Biol"},{"key":"2804_CR22","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.ymgme.2017.12.109","volume":"123","author":"C Freihuber","year":"2018","unstructured":"Freihuber C, Dahmani B, Brassier A, Brou\u00e9 P, Cances C, Chabrol B, et al. Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: a national French retrospective study. Mol Genet Metab. 2018;123:S48.","journal-title":"Mol Genet Metab"},{"key":"2804_CR23","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/jimd.12245","volume":"435","author":"MC Patterson","year":"2020","unstructured":"Patterson MC, Garver WS, Giugliani R, Imrie J, Jahnova H, Meaney FJ, et al. Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: a large retrospective observational study. J Inherit Metab Dis. 2020;435:1060\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"2804_CR24","unstructured":"Actelion. Miglustat (Zavesca\u00ae) Summary of Product Characteristics, European Medicines Agency (EudraPharm). 2010: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000435\/WC500046726.pdf."},{"key":"2804_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-018-0913-4","volume":"131","author":"Y Nadjar","year":"2018","unstructured":"Nadjar Y, Hutter-Moncada AL, Latour P, Ayrignac X, Kaphan E, Tranchant C, et al. Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect. Orphanet J Rare Dis. 2018;131:175.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR26","first-page":"2114","volume":"66","author":"B Seker Yilmaz","year":"2020","unstructured":"Seker Yilmaz B, Baruteau J, Rahim AA, Gissen P. Clinical and molecular features of early infantile Niemann Pick type C disease. Int J Mol Sci. 2020;66:2114.","journal-title":"Int J Mol Sci"},{"key":"2804_CR27","first-page":"66","volume":"93","author":"A Dardis","year":"2020","unstructured":"Dardis A, Zampieri S, Gellera C, Carrozzo R, Cattarossi S, Peruzzo P, et al. Molecular genetics of Niemann-Pick type C disease in Italy: an update on 105 patients and description of 18 NPC1 novel variants. J Clin Med. 2020;93:66.","journal-title":"J Clin Med"},{"key":"2804_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-014-0140-6","volume":"91","author":"H Jahnova","year":"2014","unstructured":"Jahnova H, Dvorakova L, Vlaskova H, Hulkova H, Poupetova H, Hrebicek M, et al. Observational, retrospective study of a large cohort of patients with Niemann-Pick disease type C in the Czech Republic: a surprisingly stable diagnostic rate spanning almost 40 years. Orphanet J Rare Dis. 2014;91:140.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1399-0004.2005.00490.x","volume":"683","author":"EM Fernandez-Valero","year":"2005","unstructured":"Fernandez-Valero EM, Ballart A, Iturriaga C, Lluch M, Macias J, Vanier MT, et al. Identification of 25 new mutations in 40 unrelated Spanish Niemann-Pick type C patients: genotype\u2013phenotype correlations. Clin Genet. 2005;683:245\u201354.","journal-title":"Clin Genet"},{"key":"2804_CR30","first-page":"66","volume":"6","author":"J Macias-Vidal","year":"2014","unstructured":"Macias-Vidal J, Giros M, Guerrero M, Gascon P, Serratosa J, Bachs O, et al. The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations. FEBS J. 2014;6:66.","journal-title":"FEBS J"},{"key":"2804_CR31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s004399900059","volume":"1051\u20132","author":"T Yamamoto","year":"1999","unstructured":"Yamamoto T, Nanba E, Ninomiya H, Higaki K, Taniguchi M, Zhang H, et al. NPC1 gene mutations in Japanese patients with Niemann-Pick disease type C. Hum Genet. 1999;1051\u20132:10\u20136.","journal-title":"Hum Genet"},{"key":"2804_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/humu.20173","volume":"261","author":"K Chikh","year":"2005","unstructured":"Chikh K, Rodriguez C, Vey S, Vanier MT, Millat G. Niemann-Pick type C disease: subcellular location and functional characterization of NPC2 proteins with naturally occurring missense mutations. Hum Mutat. 2005;261:20\u20138.","journal-title":"Hum Mutat"},{"key":"2804_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.37349\/ent.2021.00012","volume":"13","author":"X Jiang","year":"2021","unstructured":"Jiang X, Ory DS. Advancing diagnosis and treatment of Niemann-Pick C disease through biomarker discovery. Explor Neuroprotect Ther. 2021;13:146\u201358.","journal-title":"Explor Neuroprotect Ther"},{"key":"2804_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2006.05.054","volume":"2491","author":"C Iturriaga","year":"2006","unstructured":"Iturriaga C, Pineda M, Fernandez-Valero EM, Vanier MT, Coll MJ. Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci. 2006;2491:1\u20136.","journal-title":"J Neurol Sci"},{"key":"2804_CR35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajmg.b.30969","volume":"153B1","author":"NM Yanjanin","year":"2010","unstructured":"Yanjanin NM, Velez JI, Gropman A, King K, Bianconi SE, Conley SK, et al. Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet. 2010;153B1:132\u201340.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2804_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-021-01719-2","volume":"161","author":"MC Patterson","year":"2021","unstructured":"Patterson MC, Lloyd-Price L, Guldberg C, Doll H, Burbridge C, Chladek M, et al. Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale. Orphanet J Rare Dis. 2021;161:79.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13023-021-02115-6","volume":"161","author":"W Evans","year":"2021","unstructured":"Evans W, Patterson M, Platt F, Guldberg C, Mathieson T, Pacey J. International consensus on clinical severity scale use in evaluating Niemann-Pick disease Type C in paediatric and adult patients: results from a Delphi Study. Orphanet J Rare Dis. 2021;161:482.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2015.06.017","volume":"534","author":"M Di Rocco","year":"2015","unstructured":"Di Rocco M, Barone R, Madeo A, Fiumara A. Miglustat does not prevent neurological involvement in Niemann-Pick C disease. Pediatr Neurol. 2015;534: e15.","journal-title":"Pediatr Neurol"},{"key":"2804_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13023-015-0240-y","volume":"101","author":"S Fecarotta","year":"2015","unstructured":"Fecarotta S, Romano A, Della Casa R, Del Giudice E, Bruschini D, Mansi G, et al. Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C. Orphanet J Rare Dis. 2015;101:22.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2804_CR40","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1177\/0883073812464526","volume":"28","author":"P Karimzadeh","year":"2013","unstructured":"Karimzadeh P, Tonekaboni SH, Ashrafi MR, Shafeghati Y, Rezayi A, Salehpour S, et al. Effects of miglustat on stabilization of neurological disorder in Niemann-Pick disease type C: Iranian pediatric case series. J Child Neurol. 2013;28(12):1599\u2013606.","journal-title":"J Child Neurol"},{"key":"2804_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100739","volume":"27","author":"S Curelaru","year":"2021","unstructured":"Curelaru S, Zehavi Y, Almagor T, Spiegel R. Favorable outcomes following early onset oral miglustat in early infantile Niemann Pick Type C. Mol Genet Metab Rep. 2021;27: 100739.","journal-title":"Mol Genet Metab Rep"},{"key":"2804_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-019-0996-6","volume":"141","author":"M Pineda","year":"2019","unstructured":"Pineda M, Jurickova K, Karimzadeh P, Kolnikova M, Malinova V, Insua JL, et al. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease Type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis. 2019;141:32.","journal-title":"Orphanet J Rare Dis"},{"key":"2804_CR43","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ymgme.2019.02.004","volume":"1264","author":"SE Bianconi","year":"2019","unstructured":"Bianconi SE, Hammond DI, Farhat NY, Dang Do A, Jenkins K, Cougnoux A, et al. Evaluation of age of death in Niemann-Pick disease, type C: Utility of disease support group websites to understand natural history. Mol Genet Metab. 2019;1264:466\u20139.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02804-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02804-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02804-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:02:29Z","timestamp":1729785749000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02804-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02804-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2783990\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"10 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the <i>\u201cComit\u00e9 de protection des personnes\u201d (CPP)<\/i> in La Salp\u00e9tri\u00e8re Hospital (local ethic committee). For each living patient, an informed consent letter from the CRML (Reference Center for Lysosomal Diseases) was sent to parents by the referring clinician.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CF received grants from Actelion Pharmaceuticals. BH received honoraria as Member of Scientific Boards from Actelion Pharmaceuticals and Orphazyme. FL reports advisory board participation for AlfaSigma and Sanofi Genzyme, and consulting fees from AlfaSigma, Biomarin and Sanofi Genzyme. MTV received honoraria as Member of Scientific Boards from Actelion Pharmaceuticals and Orphazyme, and travel from Actelion Pharmaceuticals. PL received funding from Actelion Pharmaceuticals 2008\u20132018 for travels and practitioner\u2019s trainings.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}